BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24927267)

  • 1. Iron chelation for iron overload secondary to transfusions of packed red blood cells.
    Cid J
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):184-5. PubMed ID: 24927267
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A; Sazama K
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-chelating therapy for transfusional iron overload.
    Taccone-Gallucci M; Manca-di-Villahermosa S; Noce A
    N Engl J Med; 2011 Apr; 364(15):1476-7; author reply 1477. PubMed ID: 21488786
    [No Abstract]   [Full Text] [Related]  

  • 5. [Iron overload and iron chelation therapy in transfusion-dependent patients].
    Suzuki T
    Nihon Rinsho; 2008 Mar; 66(3):563-8. PubMed ID: 18326327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving erythropoiesis: a compelling case for iron chelation in myelofibrosis.
    Pullarkat V
    Eur J Haematol; 2016 Jun; 96(6):549-50. PubMed ID: 26572646
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogenesis of transfusional iron overload and iron chelation therapy].
    Ozawa K
    Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron-chelating therapy for transfusional iron overload.
    Solomon LR
    N Engl J Med; 2011 Apr; 364(15):1475-6; author reply 1477. PubMed ID: 21488788
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Deferiprone in Iron Chelation.
    Hider RC; Hoffbrand AV
    N Engl J Med; 2018 Nov; 379(22):2140-2150. PubMed ID: 30485781
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequences and management of iron overload in sickle cell disease.
    Porter J; Garbowski M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
    Shander A; Cappellini MD; Goodnough LT
    Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver iron overload assessment by T *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study.
    Cheng HL; Holowka S; Moineddin R; Odame I
    Am J Hematol; 2012 Apr; 87(4):435-7. PubMed ID: 22286974
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dangers of iron overload: bring in the iron police.
    Lambing A; Kachalsky E; Mueller ML
    J Am Acad Nurse Pract; 2012 Apr; 24(4):175-83. PubMed ID: 22486832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.